Kv3.3 Potassium Channel is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | Kv3.3 Potassium Channel |
|---|---|
| Gene | [KCNC3](/genes/kcnc3) |
| UniProt ID | [Q9UQ16](https://www.uniprot.org/uniprot/Q9UQ16) |
| PDB Structure | 5WRA, 6E76 |
| Molecular Weight | ~95 kDa |
| Subcellular Localization | Plasma membrane |
| Protein Family | Voltage-gated potassium channel (Kv3) |
Kv3.3 is a voltage-gated potassium channel α-subunit with:
Kv3.3 channels are essential for high-frequency neuronal firing:
Mutations in KCNC3 cause SCA13:
Pathogenic Mechanisms:
Therapeutic Implications:
The study of Kv3.3 Potassium Channel has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
NeuroWiki - Protein Page | Last Updated: 2026-03-04
The Kv3.3 channel is a potential therapeutic target for several neurological conditions. Channel blockers have been explored for treating ataxias and epileptic disorders, though specificity remains a challenge. Agonists that enhance channel function are being investigated for cognitive disorders where gamma oscillations are impaired.
| Drug/Compound | Target | Stage | Indication |
|---|---|---|---|
| 4-AP | Kv3.1-3.4 | Approved | Multiple sclerosis (Fampridine) |
| BMS-204352 | Kv3.1/Kv3.2 | Clinical | Stroke |
| PA-6 | Kv3.1 | Preclinical | Ataxia |
Current research focuses on developing subtype-selective modulators that can specifically target Kv3.3 without affecting other Kv3 channels. Gene therapy approaches using AAV vectors to deliver Kv3.3 are being explored for cerebellar ataxias. Additionally, understanding the role of Kv3.3 in GABAergic interneurons could lead to novel treatments for epilepsy and anxiety disorders.